NasdaqGS:ZBIOBiotechs
Assessing Zenas BioPharma (ZBIO) Valuation After A Strong Year And Recent Share Price Weakness
Zenas BioPharma (ZBIO), a clinical-stage immunology specialist, continues to attract attention after a year in which the stock’s total return is reported at 93.28%, contrasting with a year-to-date decline of 46.67%.
See our latest analysis for Zenas BioPharma.
At the latest share price of $18.40, Zenas BioPharma’s recent 7 day and 90 day share price returns show declines, yet its 1 year total shareholder return of 93.28% still points to earlier gains, indicating that momentum has faded...